CBD medicines available for over-the-counter sale from 2021
Investment Highlights: Althea applauds the final decision by the Therapeutic Goods Administration (TGA) to amend the current Poisons Standard to down schedule…
read moreInvestment Highlights: Althea achieved record sales of $1,190,473 in December 2020, an increase of 40% from November 2020, and the first time monthly sales have…
read more
Investment Highlights: Althea applauds the final decision by the Therapeutic Goods Administration (TGA) to amend the current Poisons Standard to down schedule…
read moreExpected from Q1 2021, Althea will import a range of Althea products into South Africa. Investment highlights: Althea has signed a wholesale supply agreement to…
read morePeak selected as the exclusive manufacturer of Tinley’s™ cannabis-infused beverages for the Canadian market. Investment highlights: Althea subsidiary Peak…
read moreAlthea is dedicated to supporting healthcare providers seeking information about and access to medicinal cannabis as a treatment option for eligible patients. One of the ways we connect with healthcare providers is by attending conferences and arranging education events.
View More Events
The growth continues! Althea has officially reached over 5,000 patients. This is an exciting milestone and a great reflection of the relentless hard work from all of the team. Thank you to all our fantastic partners and we look forward to further continued growth in 2020. https://t.co/itYfbPQHZn
read moreOur CEO Josh Fegan sat down with @CommSec's Tom Piotrowski to discuss our focus on education & technology to improve patient access to medicinal cannabis & the positive regulatory outlook for new jurisdictions & emerging markets | Video: http://ow.ly/BTEj50v0x8C
read moreAlthea is thrilled to announce that we will supply the first UK national medical cannabis pilot targeting 20,000 patients | Read the ASX announcement here: https://www.asx.com.au/asxpdf/20190625/pdf/4462xcgx974f62.pdf $AGH
read more
©2021 Althea Company Pty Ltd
